Paradigm Capital Management Inc. NY Boosts Holdings in OrthoPediatrics Corp. $KIDS

Key Points

• Paradigm Capital Management Inc. significantly increased its holdings in OrthoPediatrics Corp. by 1,607% during the first quarter, acquiring an additional 160,700 shares to own 170,700 shares valued at approximately $4.2 million.
• CFO Fred Hite purchased 5,076 shares of OrthoPediatrics, raising his ownership to 213,065 shares, amid a general trend of increased institutional investment in the company.
• Analysts have a favorable outlook for OrthoPediatrics, with a consensus rating of "Moderate Buy" and an average target price of $34.14, despite recent fluctuations in share price.

Paradigm Capital Management Inc. NY boosted its position in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 1,607.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 170,700 shares of the company's stock after acquiring an additional 160,700 shares during the quarter. Paradigm Capital Management Inc. NY owned 0.70% of OrthoPediatrics worth $4,204,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. American Century Companies Inc. raised its holdings in OrthoPediatrics by 16.1% in the first quarter. American Century Companies Inc. now owns 30,658 shares of the company's stock valued at $755,000 after acquiring an additional 4,248 shares in the last quarter. Nuveen LLC acquired a new stake in OrthoPediatrics in the first quarter valued at approximately $921,000. Invesco Ltd. raised its holdings in OrthoPediatrics by 12.1% in the first quarter. Invesco Ltd. now owns 18,349 shares of the company's stock valued at $452,000 after acquiring an additional 1,986 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in OrthoPediatrics by 46.8% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,148 shares of the company's stock valued at $348,000 after acquiring an additional 4,508 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in OrthoPediatrics by 1.5% in the first quarter. Vanguard Group Inc. now owns 937,969 shares of the company's stock valued at $23,102,000 after acquiring an additional 14,079 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

Insiders Place Their Bets

In other news, CFO Fred Hite acquired 5,076 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were purchased at an average cost of $19.41 per share, for a total transaction of $98,525.16. Following the transaction, the chief financial officer directly owned 213,065 shares in the company, valued at approximately $4,135,591.65. This represents a 2.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 32.70% of the stock is currently owned by company insiders.

OrthoPediatrics Stock Performance

Shares of KIDS traded up $0.22 during mid-day trading on Friday, reaching $20.93. 41,558 shares of the company's stock were exchanged, compared to its average volume of 194,637. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. The stock has a market capitalization of $524.61 million, a PE ratio of -11.70 and a beta of 1.06. The business's fifty day simple moving average is $21.10 and its 200-day simple moving average is $22.03. OrthoPediatrics Corp. has a 52-week low of $16.59 and a 52-week high of $33.14.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. The business had revenue of $61.08 million for the quarter, compared to analyst estimates of $61.40 million. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. OrthoPediatrics has set its FY 2025 guidance at EPS. On average, equities research analysts expect that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on KIDS. Piper Sandler reduced their target price on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Thursday, May 8th. JMP Securities set a $35.00 price objective on shares of OrthoPediatrics and gave the stock a "market outperform" rating in a report on Friday, August 8th. Wall Street Zen raised shares of OrthoPediatrics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, BTIG Research cut their price objective on shares of OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $34.14.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.